iShares Evolved U.S. Innovative Healthcare ETF (IEIH)

BATS: IEIH · IEX Real-Time Price · USD
34.12
+0.23 (0.67%)
At close: Aug 5, 2022 4:00 PM
34.42
+0.30 (0.88%)
After-hours: Aug 8, 2022 8:00 PM EDT
0.67%
Assets $37.57M
NAV $34.15
Expense Ratio 0.18%
PE Ratio 15.79
Shares Out 1.10M
Dividend (ttm) $0.96
Dividend Yield 2.82%
Ex-Dividend Date Jun 9, 2022
1-Year Return -6.74%
Volume 4,420
Open 34.00
Previous Close 33.89
Day's Range 34.12 - 34.31
52-Week Low 30.66
52-Week High 37.65
Beta 0.68
Holdings 266
Inception Date Mar 21, 2018

About IEIH

The fund invests, under normal circumstances, at least 80% of its net assets in U.S. listed common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. It will hold common stock of those companies that fall into the Innovative Healthcare Evolved Sector which have economic characteristics that have been historically correlated with companies traditionally defined as pharmaceutical and biotechnology companies. The fund is non-diversified.

Asset Class Equity
Region North America
Issuer BlackRock iShares
Stock Exchange BATS
Ticker Symbol IEIH
Index Tracked MSCI USA IMI Health Care Index

Top 10 Holdings

59.34% of assets
Name Symbol Weight
Johnson & Johnson JNJ 9.83%
BLK CSH FND TREASURY SL AGENCY XTSLA 8.02%
Eli Lilly and Company LLY 6.75%
AbbVie ABBV 5.73%
Merck & Co. MRK 5.53%
Vertex Pharmaceuticals VRTX 5.16%
Bristol-Myers Squibb Company BMY 5.13%
Moderna MRNA 4.82%
Amgen AMGN 4.27%
Regeneron Pharmaceuticals REGN 4.09%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Jun 9, 2022 $0.08184 Jun 15, 2022
Mar 24, 2022 $0.14879 Mar 30, 2022
Dec 13, 2021 $0.60844 Dec 17, 2021
Sep 24, 2021 $0.12464 Sep 30, 2021
Jun 10, 2021 $0.08647 Jun 16, 2021
Mar 25, 2021 $0.10641 Mar 31, 2021
Full Dividend History

News

JNJ Beats on Q2 Earnings, Cuts View: ETFs in Focus

Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.

Other symbols: IHEIYHVHTXLV

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

iShares To Close 11 ETFs In August

The issuer typically closes a handful of funds during the month every year.

BlackRock Announces Product Updates to 11 U.S.-listed ETFs

NEW YORK--(BUSINESS WIRE)--iShares today announced its plans to close the following U.S. -listed ETFs on August 25, 2022. Ticker Fund Name AGT iShares MSCI Argentina and Global Exposure ETF EMBH iShares...

5 ETFs to Counter Imminent War-Induced Global Growth Slowdown

The pandemic-driven supply chain woes and the resultant red-hot inflation, the Russia-Ukraine war and the resultant hit to the commodity market as well as the central banks' policy tightening in the dev...

Other symbols: RINGSPLVVDCVIGI

Warm Up Your Portfolio With These ETFs This Winter

Uncertainties are playing a big role in the Wall Street due to record-high inflation, Fed policy tightening and Omicron strain of coronavirus. Still, some ETFs may warm up your winter portfolio.

Other symbols: FDLRHSVTVXLRE

Take a Look at the Top-Performing Biotech ETFs YTD

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Other symbols: BBHBIBIBBIDNA

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...

Other symbols: BBCBNTXCERECNCRPFE

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Other symbols: FXHIHEPJPPPH

Time for Pharma and Healthcare ETFs?

The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales

Other symbols: BBHFXHIYH

2 Sector ETFs Hovering Around All-Time Highs

The U.S. economic backdrop and investors' sentiments have remained mixed in recent weeks.

How To Legally Dodge Biden's Capital Gains Tax In Your Portfolio

Biden's proposal to nearly double the capital gains tax rate is unnerving investors. But there's a legal way to dodge them.

Other symbols: IVVQQQSPYVOOVTI

Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause

Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...

Other symbols: BBHFHLCIHE

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Other symbols: FDLFTXHIHE

ETFs to Shine as Pfizer's COVID-19 Vaccine Gets a Nod in Europe

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.

Other symbols: DHSFDLFTXHHDV

ETF Tax Benefits Continued In 2020

Capital gains are rare in the ETF space, but there are always some.

Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas

Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.

Other symbols: BBHBIIBFXGIBBKR

JNJ Beats, Ups View: Healthcare ETFs to Buy

Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.

Other symbols: IHEIYHVHTXLV

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Other symbols: BBHIBBPBEPJP

Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat

Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.

Other symbols: IHEIYHVHTXLV